2016
DOI: 10.1038/bmt.2016.228
|View full text |Cite
|
Sign up to set email alerts
|

Autoimmune hemolysis and immune thrombocytopenic purpura after cord blood transplantation may be life-threatening and warrants early therapy with rituximab

Abstract: Autoimmune hemolysis (AH) and immune thrombocytopenic purpura (ITP) are recognized complications after cord blood transplantation (CBT). We evaluated the incidence and characteristics of AH/ ITP after double-unit CBT in a day 100 landmark analysis of 152 patients (median age 36 years, range 0.9–70) transplanted for hematologic malignancies with myeloablative or non-myeloablative conditioning and calcineurin-inhibitor (CNI)/ mycophenolate mofetil. With a median 5.2 year (range 1.6–9.7) survivor follow-up, 10 pa… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2

Citation Types

1
14
0

Year Published

2017
2017
2023
2023

Publication Types

Select...
5

Relationship

0
5

Authors

Journals

citations
Cited by 14 publications
(15 citation statements)
references
References 21 publications
1
14
0
Order By: Relevance
“…AH/ITP can be both abrupt in onset and life-threatening 109111 . High rates of immune cytopenias have been reported in pediatric patients undergoing CBT in the first year of life 112 .…”
Section: Other Complicationsmentioning
confidence: 99%
See 1 more Smart Citation
“…AH/ITP can be both abrupt in onset and life-threatening 109111 . High rates of immune cytopenias have been reported in pediatric patients undergoing CBT in the first year of life 112 .…”
Section: Other Complicationsmentioning
confidence: 99%
“…High rates of immune cytopenias have been reported in pediatric patients undergoing CBT in the first year of life 112 . Early intervention with corticosteroids and rituximab at diagnosis is effective and early rituximab administration is a corticosteroid sparing strategy in patients with severe disease 111 .…”
Section: Other Complicationsmentioning
confidence: 99%
“…When identified early, initiation of first‐line therapy with corticosteroids is appropriate. Patients who do not respond to steroids should receive treatment with rituximab . Long‐term courses of corticosteroids should be avoided to minimize long‐term side effects, which may be more intensified in this patient population with significant underlying comorbidities and concomitant therapies.…”
Section: Discussionmentioning
confidence: 99%
“…Patients should be monitored long‐term for these complications and prompt treatment should be initiated when identified. Early use of rituximab may reduce the long‐term complications of corticosteroid use and is successful in about 60% of patients . Further research is still needed, however, to better understand the immunology behind these conditions and determination of more targeted therapeutic options.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation